Guselkumab vs Golimumab in PsA TNF Inadequate Responder Patients (EVOLUTION)

Condition:   Psoriatic Arthritis Interventions:   Drug: Guselkumab;   Drug: Golimumab Sponsors:   University of Pennsylvania;   Janssen Scientific Affairs, LLC Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials